Caspase-3/7 activator 4
Caspase-3/7 activator 4 is a caspase-3 activator and caspase-7 activator. Caspase-3/7 activator 4 inhibits key enzymes in estrogen biosynthesis, including aromatase (IC50 = 38.3 nM) and steroid sulfatase (IC50 = 12.7 µM), and selectively suppresses COX-2 (IC50 = 5.38 µM). Caspase-3/7 activator 4 shows strong antioxidant activity (DPPH: IC50 = 16.26 µM). Caspase-3/7 activator 4 inhibits estrogen synthesis, suppresses estrogen availability, reduces prostaglandin production, increases caspase-3/7 expression, induces G0/G1 cell cycle arrest, induces apoptotic cell death, reduces circulating TNF-α and VEGFR-II levels, restores hepatorenal function markers and histoarchitecture, restores antioxidant defense enzyme activity, reduces lipid peroxidation, exerts antiproliferative activity against breast cancer cells, exerts antitumor activity in the Ehrlich ascites carcinoma models. Caspase-3/7 activator 4 can be used for the research of breast cancer, ehrlich ascites carcinoma.
For research use only. We do not sell to patients.
- Formula: C14H14ClN3O4S
- Molecular Weight:355.80
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
COX-2 5.38 μM (IC50) |
Caspase 3 |
Caspase-7 |
Aromatase 38.3 μM (IC50) |
Steroid Sulfatase 12.7 μM (IC50) |
In Vitro
Caspase-3/7 activator 4 (compound 6) (0.5-80 μM; hibits the proliferation of MDA-MB-231 and MCF-7 breast cancer cells with IC50 values of 2.25 μM and 6.70 μM, respectively, and shows high selectivity for cancer cells over non-tumorigenic MCF-10A cells[1].
Caspase-3/7 activator 4 (2.25 μM; 24 h) induces G0/G1 cell cycle arrest in MDA-MB-231 cells[1].
Caspase-3/7 activator 4 (2.25 μM; 24 h) induces substantial apoptotic cell death in MDA-MB-231 cells, with early apoptosis as the predominant mode[1].
Caspase-3/7 activator 4 (2.25 μM; 24 h) activates caspase-3 and caspase-7 in MDA-MB-231 cells, indicating induction of apoptotic pathways[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231, MCF-7, MCF-10A
-
Concentration:0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, 80 μM
-
Incubation Time:48 h
-
Result:Exhibited potent antiproliferative activity with IC50 values of 2.25 μM against MDA-MB-231 cells, 6.70 μM against MCF-7 cells, and 36.57 μM against non-tumorigenic MCF-10A cells.
-
Cell Line:MDA-MB-231
-
Concentration:2.25 μM
-
Incubation Time:24 h
-
Result:Induced a substantial accumulation in the G0/G1 phase (84.62%) with a concomitant decrease in the S phase (12.83%) and G2/M phase (2.55%) compared to untreated control cells.
-
Cell Line:MDA-MB-231
-
Concentration:2.25 μM
-
Incubation Time:24 h
-
Result:Resulted in a markedly higher total apoptosis/necrosis rate (24.81%) compared to untreated control cells (2.46%), with 16.26% early apoptosis, 5.61% late apoptosis, and 2.94% necrosis.
-
Cell Line:MDA-MB-231
-
Concentration:2.25 μM
-
Incubation Time:24 h
-
Result:Significantly increased caspase-3 levels to 428.56 pg/mL (3.69-fold increase) and caspase-7 levels to 2.916 ng/mL (4.83-fold increase) compared to untreated controls.
In Vivo
Caspase-3/7 activator 4 (1-200 mg/kg; i.p.; once) is administered to mice and closely monitored for 48 hours for death, behavioral changes, and obvious toxic symptoms. At doses up to 120 mg/kg , no mortality or abnormal behavioral manifestations were observed, and the animals maintained normal grooming, feeding, and locomotor activity, indicating a good safety margin at these concentra-
tions. In contrast, administration of 200 mg/kg resulted in complete mortality, establishing this dose as the approximate lethal dose (LD100)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss albino female (20-25 g, Ehrlich ascites carcinoma model)[1]
-
Dosage:2.5, 5, 10, 15, and 20 mg/kg
-
Administration:i.p.; every other day; 10 days
-
Result:Reduced viable EAC cell count to 125.94 × 106 (39.7% decrease vs. control) at 2.5 mg/kg.
Reduced viable EAC cell count to 78.76 × 106 (62.3% decrease vs. control) at 5 mg/kg.
Reduced viable EAC cell count to 58.64 × 106 (71.9% decrease vs. control) at 10 mg/kg.
Reduced viable EAC cell count to 42.17 × 106 (79.8% decrease vs. control) and ascitic tumor volume to 1.45 mL (74.3% decrease vs. control) at 15 mg/kg; reduced viable EAC cell count to 37.67 × 10⁶ (81.9% decrease vs. control) at 20 mg/kg; reduced serum TNF-α levels to 82.27 pg/mL (vs. EAC control 162.63 pg/mL); reduced serum VEGFR-II levels to 46.59 ng/mL; restored liver antioxidant markers (GSH: 31.20 pg/g tissue, CAT: 35.90 U/g tissue, SOD: 31.86 U/g tissue) and reduced MDA to 27.65 nmol/g tissue; improved liver function (ALT: 67.50 U/L, AST: 84.5 U/L) and renal function (creatinine: 0.98 mg/dL, urea: 60.50 mg/dL) vs. EAC control.
Chemical Information
-
Molecular Weight 355.80
-
Formula C14H14ClN3O4S
-
SMILES
O=C(OC)CCN1/C(SCC1=O)=N\N=C\C2=CC(Cl)=CC=C2O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
[1]. El-Zend MA, et al. Design, synthesis, and multi-target anticancer evaluation of 1,3-thiazolodin-4-one analogues against breast cancer: mechanistic insights into estrogen metabolism, inflammation, angiogenesis, and oxidative stress. RSC Adv. 2026;16(3):2528-2554. Published 2026 Jan 12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)